Study Reveals Platelet Counts Decrease for All Women During Pregnancy
Gestational thrombocytopenia (defined as a platelet count <150,000/mm3 during uncomplicated pregnancy) has been recognized for more than 25 years, but the course of platelet...
Somatic Mutations and Co-Mutations Predict AML Risk in Women
According to results from a deep-sequencing analysis published in Nature Medicine, women with mutations of the TP53 and IDH genes in the absence of...
Extended Analysis Shows Venetoclax Continues to Produce Deep Responses in CLL
In 2016, the U.S. Food and Drug Administration granted venetoclax accelerated approval for the treatment of adults with previously treated chronic lymphocytic leukemia (CLL)...
Denosumab Versus Zoledronic Acid for Reducing Time to Skeletal Events in Multiple Myeloma
Approximately 90 percent of patients diagnosed with multiple myeloma (MM) present with bone lesions and are typically treated with zoledronic acid (ZA), a potentially...
Ibrutinib and Venetoclax Combo Confers High Response in Mantle-Cell Lymphoma
In results from a phase II study published in The New England Journal of Medicine, the combination of the Bruton tyrosine kinase (BTK) inhibitor...
Adding Carfilzomib to Lenalidomide and Dexamethasone Extends Overall Survival in Multiple Myeloma
Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of adverse events (AEs) in patients...
EURO-SKI: Can Patients With CML Stop Tyrosine Kinase Inhibitors?
Treatment with tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib, has increased the rates of survival and response over previously available therapies for...
NYC Firefighters Exposed to World Trade Center Disaster Have Increased Myeloma Risk
New York City firefighters who were exposed to chemicals released into the environment following the World Trade Center (WTC) attacks on September 11, 2001,...
Presence of Minimal Residual Disease Predicts Relapse and Survival in AML
For patients with acute myeloid leukemia (AML), the detection of molecular minimal residual disease (MRD) in patients achieving morphologic complete remission (CR) was associated...
Complete Mutation Clearance Predicts Longer Survival and Lower Relapse Risk in AML
Somatic mutation clearance (MC) at complete remission (CR) of acute myeloid leukemia (AML) was associated with improved survival and reduced risk of relapse, according...
Current Issue
September 2018, Volume 4, Issue 11
View issue flipbook
September 2018
Volume 4, Issue 11This issue features a look at research misconduct, a debate about whether chronic lymphocytic leukemia is curable, and...
